ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Michigan » Pulmonary Disease

Top Pulmonary Disease Prescribers in Michigan

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
CHAKRADHAR REDDY MD

Pulmonary Disease

9,149

$434K

391
346 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

19%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 60%

$47
Average prescription price

Avg: $202

TARIQ ABDELKARIM M.D.

Pulmonary Disease

7,159

$783K

567
403 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

47%
prescriptions for brand name drugs

Avg: 60%

$109
Average prescription price

Avg: $202

WILLIAM DECKER D.O.

Pulmonary Disease

6,896

$497K

509
366 are 65+

7%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 60%

$72
Average prescription price

Avg: $202

ALI HAIDAR M.D.

Pulmonary Disease

5,717

$604K

540
442 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 60%

$106
Average prescription price

Avg: $202

ARSENIO DE LEON M.D.

Pulmonary Disease

3,947

$286K

241
215 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 60%

$73
Average prescription price

Avg: $202

MICHAEL BASHA D.O.

Pulmonary Disease

3,871

$902K

420
330 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 60%

$233
Average prescription price

Avg: $202

KANWAR MENDIRATTA M.D.

Pulmonary Disease

3,715

$185K

215
97 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

40%
patients receiving schedule three controlled substances

Avg: 2%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 60%

$50
Average prescription price

Avg: $202

LONNIE JOE M.D.

Pulmonary Disease

3,711

$251K

183
134 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 60%

$68
Average prescription price

Avg: $202

STEVEN KRAKER MD

Pulmonary Disease

3,394

$824K

435
352 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 60%

$243
Average prescription price

Avg: $202

NADINE POTEMPA MD

Pulmonary Disease

3,204

$579K

397
295 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 60%

$181
Average prescription price

Avg: $202

ANJALI KUMAR MD

Pulmonary Disease

3,111

$143K

150
76 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

33%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 60%

$46
Average prescription price

Avg: $202

DAVID PAYNE MD

Pulmonary Disease

2,905

$389K

287
234 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

49%
prescriptions for brand name drugs

Avg: 60%

$134
Average prescription price

Avg: $202

TAMARA MOUTSATSON DO

Pulmonary Disease

2,861

$157K

150
115 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 60%

$55
Average prescription price

Avg: $202

ARTHUR SAARI M.D.

Pulmonary Disease

2,693

$198K

220
181 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 60%

$73
Average prescription price

Avg: $202

VASKEN ARTINIAN M.D.

Pulmonary Disease

2,637

$483K

349
252 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

46%
prescriptions for brand name drugs

Avg: 60%

$183
Average prescription price

Avg: $202

JOHN GOBEL

Pulmonary Disease

2,508

$240K

164
132 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

25%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 60%

$96
Average prescription price

Avg: $202

MOHAMMAD FARRA MD

Pulmonary Disease

2,481

$382K

388
313 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 60%

$154
Average prescription price

Avg: $202

KEVIN KYLE MD

Pulmonary Disease

2,145

$949K

127
74 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 60%

$442
Average prescription price

Avg: $202

ROBERT VACLAV D.O.

Pulmonary Disease

2,124

$162K

219
179 are 65+

8%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 60%

$76
Average prescription price

Avg: $202

TAMMY OJO MD

Pulmonary Disease

2,123

$401K

104
60 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 60%

$189
Average prescription price

Avg: $202

ROBERT PIASECKI DO

Pulmonary Disease

2,021

$457K

315
257 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 60%

$226
Average prescription price

Avg: $202

DALE COLLER DO

Pulmonary Disease

1,939

$311K

202
125 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

49%
prescriptions for brand name drugs

Avg: 60%

$160
Average prescription price

Avg: $202

ALFONSO O'NEILL M.D.

Pulmonary Disease

1,900

$486K

300
259 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 60%

$256
Average prescription price

Avg: $202

MARC DUNN M.D.

Pulmonary Disease

1,856

$451K

283
258 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 60%

$243
Average prescription price

Avg: $202

KEVIN CHAN MD

Pulmonary Disease

1,801

$253K

78
32 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 60%

$140
Average prescription price

Avg: $202

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank